188 related articles for article (PubMed ID: 23380419)
1. Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host.
Saporito L; Giammanco GM; De Grazia S; Colomba C
Int J Infect Dis; 2013 Aug; 17(8):e572-6. PubMed ID: 23380419
[TBL] [Abstract][Full Text] [Related]
2. Host resistance to visceral leishmaniasis: prevalence and prevention.
Maran N; Gomes PS; Freire-de-Lima L; Freitas EO; Freire-de-Lima CG; Morrot A
Expert Rev Anti Infect Ther; 2016; 14(4):435-42. PubMed ID: 26934623
[TBL] [Abstract][Full Text] [Related]
3. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
Gravino AE
Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
[TBL] [Abstract][Full Text] [Related]
4. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
McMahon-Pratt D; Alexander J
Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
[TBL] [Abstract][Full Text] [Related]
5. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis.
Engwerda CR; Ato M; Kaye PM
Trends Parasitol; 2004 Nov; 20(11):524-30. PubMed ID: 15471704
[TBL] [Abstract][Full Text] [Related]
6. Imaging visceral leishmaniasis in real time with golden hamster model: Monitoring the parasite burden and hamster transcripts to further characterize the immunological responses of the host.
Rouault E; Lecoeur H; Meriem AB; Minoprio P; Goyard S; Lang T
Parasitol Int; 2017 Feb; 66(1):933-939. PubMed ID: 27794505
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature.
Antinori S; Calattini S; Longhi E; Bestetti G; Piolini R; Magni C; Orlando G; Gramiccia M; Acquaviva V; Foschi A; Corvasce S; Colomba C; Titone L; Parravicini C; Cascio A; Corbellino M
Clin Infect Dis; 2007 Jun; 44(12):1602-10. PubMed ID: 17516404
[TBL] [Abstract][Full Text] [Related]
8. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
9. Chemokines in host-parasite interactions in leishmaniasis.
Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A
Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413
[TBL] [Abstract][Full Text] [Related]
10. Imaging host-Leishmania interactions: significance in visceral leishmaniasis.
Forestier CL
Parasite Immunol; 2013; 35(9-10):256-66. PubMed ID: 23772814
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antivirals and visceral leishmaniasis: a case report.
Colomba C; Saporito L; Di Carlo P; Tolomeo M; Cervo A; Firenze A; Trizzino M; Cascio A
BMC Infect Dis; 2019 Apr; 19(1):328. PubMed ID: 30999874
[TBL] [Abstract][Full Text] [Related]
12. Impact of a co-factor on the dynamics of Leishmania donovani infection: does HIV infection encourage the recurrence of visceral leishmaniasis following post-kala-azar dermal leishmaniasis?
Nandy A; Addy M; Maji AK; Guha SK
Ann Trop Med Parasitol; 2004 Sep; 98(6):651-4. PubMed ID: 15324473
[No Abstract] [Full Text] [Related]
13. Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis.
Saha B; Tonkal AM; Croft S; Roy S
Clin Exp Immunol; 2004 Jul; 137(1):19-23. PubMed ID: 15196239
[TBL] [Abstract][Full Text] [Related]
14. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
Reiner NE
J Immunol; 1987 Mar; 138(6):1919-25. PubMed ID: 3493291
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas?
Weisser M; Khanlari B; Terracciano L; Arber C; Gratwohl A; Bassetti S; Hatz C; Battegay M; Flückiger U
Clin Microbiol Infect; 2007 Aug; 13(8):751-3. PubMed ID: 17610597
[TBL] [Abstract][Full Text] [Related]
16. Visceral leishmaniasis with special reference to Egypt (review and comment).
Morsy TA
J Egypt Soc Parasitol; 1997 Aug; 27(2):373-96. PubMed ID: 9257976
[TBL] [Abstract][Full Text] [Related]
17. Determinants for the development of visceral leishmaniasis disease.
McCall LI; Zhang WW; Matlashewski G
PLoS Pathog; 2013 Jan; 9(1):e1003053. PubMed ID: 23300451
[TBL] [Abstract][Full Text] [Related]
18. Human hepatic stellate cells in primary culture are safe targets for Leishmania donovani.
Rostan O; Robert-Gangneux F; Lambert M; Samson M; Gangneux JP
Parasitology; 2013 Apr; 140(4):471-81. PubMed ID: 23253952
[TBL] [Abstract][Full Text] [Related]
19. Visceral and cutaneous leishmaniasis comparative ultrastructure of host-parasite interactions.
el-Shoura SM; Sheikha AK; Bahamdan KA; Tallab TM; Hassounah OA
J Egypt Soc Parasitol; 1995 Dec; 25(3):861-76. PubMed ID: 8586879
[TBL] [Abstract][Full Text] [Related]
20. Delineating infection strategies of Leishmania donovani secretory proteins in Human through host-pathogen protein Interactome prediction.
Panditrao G; Ganguli P; Sarkar RR
Pathog Dis; 2021 Nov; 79(8):. PubMed ID: 34677584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
